Allergan plc (AGN): Incrementally Cautious - Piper Jaffray
Get Alerts AGN Hot Sheet
Rating Summary:
9 Buy, 20 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Piper Jaffray analyst, David Amsellem, is cautious on Allergen (NYSE: AGN) despite bright spots in the quarter. The company needs incremental products to growth the top line leaving the path to growth murky.
AGN reported non-GAAP diluted EPS of $3.04 on revenues of $3.8B, versus the Street estimates of $3.00 and $3.95B, respectively. There are bright spots such as Botox and Linzess but top-line was pressured in part due to 1Q seasonality. The analyst has concerns regarding the long-term growth trajectory of the top-line given the question marks surrounding key components of the base business (i.e., maturing/declining assets; patent expiries longer term (e.g. Bystolic, Viibryd)).
Value creation is largely dependent on the late-stage pipeline bearing fruit and bolt-on M&A. No change to Neutral rating and reducing the PT to $236 from $238.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $225.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- QuantumScape (QS) PT Lowered to $6 at Truist Securities
- AutoCanada Inc. (ACQ:CN) (AOCIF) PT Raised to Cdn$25 at CIBC
- Fortis Inc. (FTS:CN) (FTS) PT Lowered to Cdn$56 at CIBC
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!